Top 20 Shareholders in Annual Report 2023
Top 20 Shareholders in Annual Report 2022
Last Appendix 3Y I could find.
JP Morgan have increased their holdings but all other nominees have reduced. Other top 20s also selling.
Abbotsleigh seem to have sold down another 3 million since December 2022 but I cant find another 3Y. Unless there is an exemption under the Corporations Act that permits no disclosure from a Director with an Indirect Holding. In the Annual Report 2022 there was no Abbotsleigh, just all securities held by Ian Gandel. Abbotsleigh could be selling, or I have missed a 3Y, or the 3 million is still held by a nominee. Someone else may be able to help me out here.
Its beginning to get fairly clear to me that large holders are reducing their holdings as a ripple affect to Ian Gandel selling down his securities. And rightly so, IMO. It would be nice to know where Ian Gandel stands in respect to Alkane and if further selling is required in relation to furthering his interests Alliance Resources, future CRs etc...
- Forums
- ASX - By Stock
- ALK
- Ann: Annual Report to shareholders
Ann: Annual Report to shareholders, page-48
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALK (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.5¢ |
Change
-0.025(4.81%) |
Mkt cap ! $299.5M |
Open | High | Low | Value | Volume |
50.0¢ | 50.0¢ | 48.0¢ | $731.1K | 1.485M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33631 | 49.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 12456 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 33631 | 0.490 |
2 | 12800 | 0.485 |
4 | 113156 | 0.480 |
2 | 40000 | 0.475 |
6 | 127015 | 0.470 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 12456 | 3 |
0.500 | 21800 | 2 |
0.505 | 7800 | 1 |
0.515 | 2015 | 1 |
0.520 | 53288 | 5 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
ALK (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online